For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced further positive results of data analysis from a phase 1c clinical trial (MF-101) studying its drug PXS-5505 in patients with the bone marrow cancer myelofibrosis for 28 days at three dosage levels.
Assessment with Pharmaxis’ proprietary assays of the highest dose has shown inhibition of the target enzymes, LOX and LOXL2, at greater than 90% over a 24-hour period at day 7 and day 28. The trial safety committee has reviewed the results and having identified no safety signals, has cleared the study to progress to the phase 2 dose expansion phase where 24 patients will be treated at the highest dose twice a day for 6 months.Read full media release - pdf
Pharmaxis Ltd (ASX: PXS) chief executive officer Mr Gary Phillips will present at the Monsoon Communications and Peak Asset Management Biotech Webinar on Monday 27 September at 11:00am AEST. The webinar will also feature presentations from Avita Medical, Biotron and Avecho Biotech.
Shareholders and investors are invited to participate in this free event.
Investors should register in advance to participate using the following registration link:
- Topical treatment safe and well tolerated in study of healthy volunteers
- Full inhibition of lysyl oxidase enzymes achieved in skin with minimal systemic exposure
- Collaboration with research team led by Professor Fiona Wood AM planning for trial in patients with established scars to commence in Q4 2021